12 May 2017 | News
Sofie Biosciences, Inc. is a developer of molecular imaging diagnostics and technologies to empower widespread access to Positron Emission Tomography (PET).
Sofie Biosciences, Inc. has entered into a definitive agreement under which it will purchase Zevacor Pharma (previously IBA Molecular North America) and its high-performance manufacturing and distribution network of PET imaging diagnostics and radio-therapeutics.
Sofie Biosciences, Inc., (SOFIE) is a developer of molecular imaging diagnostics and technologies to empower widespread access to Positron Emission Tomography (PET).
Zevacor Pharma, currently owned by Illinois Health and Science (IHS), is a highly valuable asset, full of talented employees who ensure patients have access to advanced imaging and treatment. The combined capabilities will provide customers with an ecosystem of PET products from imaging diagnostics to chemistry technologies for manufacturing of new compounds, to PET imaging systems.
Customers and partners will greatly benefit from SOFIE taking commercial leadership in the PET radio-pharmacy industry to not only grow FDG PET/CT service, which is still vastly underutilized, but expand the use of newly FDA-approved PET diagnostics, support Phase I/II/III clinical trials, and enable the preclinical sciences with expanding access to PET, in concert with the pipeline of imaging diagnostics.